Not Disclosed Neurodegeneration by Eli Lilly and Co for Neurodegenerative Diseases: Likelihood of Approval

Not Disclosed Neurodegeneration is under clinical development by Eli Lilly and Co and currently in Phase I for Neurodegenerative Diseases.

Diet-related inflammation may raise stroke risk, US study finds

The relationship between the dietary inflammatory index (DII) and stroke incidence.

January 4, 2024

Impact of diet on health outcomes among United Kingdom Biobank participants

The association between diet and health outcomes among United Kingdom Biobank (UKBB) participants.

February 16, 2024

Endo Health ordered to pay more than $1.5 billion in opioid criminal case

In the second-largest fine ever levied on a pharmaceutical company, Endo Health Solutions was ordered to pay nearly $1.1 billion in criminal penalties and another

May 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.